Tesamorelin Tesamorelin is an FDAapproved peptide for reducing visceral fat, particularly in HIVassociated lipodystrophy, and has robust clinical evidence behind it: Tesamorelin stimulates growth hormone release more effectively than AOD9604
Many recipients report faster, more noticeable results compared to oral supplementation
The digestive bypass ensures they receive therapeutic B12 levels regardless of gut health status
It is associated with supporting the bodys ability to manage excess fat while improving overall metabolic efficiency
human bioavailability is unknown Subcutaneous injection Human subcutaneous bioavailability and pharmacokinetics are unknown Factor Convenience Oral capsules No mixing or syringe math Subcutaneous injection Requires reconstitution, sterile supplies, and injection-site planning Factor Evidence limits Oral capsules No controlled human dose, benefit, or safety trial Subcutaneous injection No controlled human dose, benefit, or safety trial Factor Can the amounts be treated as equal